RxDoctor Payments Data

Donald Russo, MD

Cardiovascular Disease · Hendersonville, TNNPI 1790891315

Payments from drug & device makers

$9,543in general payments, 2019–2025

Across 540 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Johnson & Johnson$954
  • Boston Scientific$788
  • Boehringer Ingelheim$674
  • Novo Nordisk$662
  • E.r. Squibb & Sons, L.L.C.$625
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$9,38198%
  • Education$1622%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,543 in reported general payments places this provider in the 75th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$205,397
Medicare patients
937
Services billed
3,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban415$453,475
JardianceEmpagliflozin350$393,478
OzempicSemaglutide275$315,368
Repatha SureclickEvolocumab346$293,004
MounjaroTirzepatide181$209,830
EntrestoSacubitril/Valsartan116$153,553
TrulicityDulaglutide124$152,293
XareltoRivaroxaban138$148,954
WegovySemaglutide32$44,352
RybelsusSemaglutide40$40,566
NexlizetBempedoic Acid/Ezetimibe57$39,154
FarxigaDapagliflozin Propanediol23$33,000
VerquvoVericiguat12$20,051
Ezetimibe545$18,535
VascepaIcosapent Ethyl20$18,321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$562$453,475415 claims
Novo NordiskOzempic, Wegovy, Rybelsus$662$400,286347 claims
Boehringer IngelheimJardiance$674$393,478350 claims
Lilly USA, LLCMounjaro, Trulicity$115$362,123305 claims
NovartisEntresto$485$153,553116 claims
Johnson & JohnsonXarelto$954$148,954138 claims
Esperion Therapeutics, Inc.Nexlizet$136$39,15457 claims
AstraZenecaFarxiga$603$33,00023 claims
MerckVerquvo$253$20,05112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Hendersonville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →